Raltegravir (MK-0518)

• CAT Number: A000442
• CAS Number: 518048-05-0
• Molecular Formula: C20H21FN6O5
• Molecular Weight: 444.40
• Purity: ≥95%
• Target: HIV Integrase
• Solubility: >20mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
• InChI: InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
• InChIKey: CZFFBEXEKNGXKS-UHFFFAOYSA-N
• SMILES: CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F

Raltegravir (MK-0518)（Cat No.:A000442）is an antiretroviral medication used to treat HIV-1 infection by inhibiting the viral enzyme integrase. As an integrase strand transfer inhibitor (INSTI), raltegravir prevents the integration of viral DNA into the host cell genome, a critical step in HIV replication. This mechanism effectively reduces viral load and enhances immune function, making it a cornerstone in HIV therapy, especially in combination with other antiretrovirals. Raltegravir’s potency, favorable safety profile, and minimal drug-drug interactions make it a widely used option in first-line and salvage HIV treatments.